

R&D WHITE
SPACE ANALYSIS




DATA-DRIVEN R&D STRATEGY

Harnessing global trial data points into your next
strategic R&D investment

GET STARTED




AACT DASHBOARD | Overview



AACT DASHBOARD | Sponsors




Total Number of Trials by sponsors




Total Number of Trials by phase


- Not Applicable
- PHASE 1
- PHASE 2
- PHASE 3
- PHASE 4




Number of Sponsors per Condition



SALES DASHBOARD | Opportunity




Cardiovascular	Inflammatory & Autoimmune	Musculoskeletal
Central Nervous System	Mental Health	Oncology >
Infectious Disease	Metabolic	Pain & Anesthesiology






SALES DASHBOARD | Studies




solid tumor
cancer



40

Number of Sponsors



brief_title	year	overall_status	phase	sponsor_name	why_stopped
Study of GV20-0251 in Participants With Solid Tumor Malignancies	2025	Active	PHASE 2	GV20 Therapeutics	No Comment
Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)	2025	Active	PHASE 2	Avenzo Therapeutics, Inc.	No Comment

